SecBot SecBot
8-K ·Filed Mar 5, 2026

SLN

Silence Therapeutics plc
MIXED
Impact 6/10
Horizonmonths Processed8mo ago SEC0001193125-26-092578
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

Monitor the upcoming topline results from the Phase 2 SANRECO trial in Q3 2026, which could be a major value driver. The company's ability to secure partnerships for its Phase 3-ready zerlasiran program and advance its preclinical pipeline will be key indicators of future success. The cash position appears sufficient to fund operations through the near-term catalysts.

DirectionMixed
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$5.50
T+0 close · Mar 5, 2026 · via day close
Latest settled
+18.73%
T+60 · $6.53
Vs SPY
+7.43%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 5 $5.50entry
  2. T+1 · 9mo ago +13.27%α +14.59% · $6.23
  3. T+5 · 8mo ago +26.73%α +28.96% · $6.97
  4. T+20 · 8mo ago +8.00%α +11.79% · $5.94
  5. T+60 · 6mo ago +18.73%α +7.43% · $6.53
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Silence Therapeutics reported a significant year-over-year decline in revenue and increased net loss, driven by the conclusion of prior collaborations. However, the company highlighted positive clinical progress, including accelerated topline results for its divesiran trial in polycythemia vera expected in Q3 2026, and promising preclinical data for new siRNA programs. The cash position of $85.1 million provides runway for ongoing development.

Key Financial Metrics

Revenue
$559.0K
-98.7% YoY
EPS
$-63.00

Key Facts

  • Revenue dropped 98.7% YoY to $0.6 million due to conclusion of Hansoh collaboration and reduced AstraZeneca revenue
  • Net loss increased 95.5% YoY to $88.6 million
  • Cash position of $85.1 million as of December 31, 2025
  • Topline results for Phase 2 SANRECO trial of divesiran in polycythemia vera expected in Q3 2026 (accelerated from H2 2026)
  • AstraZeneca will not pursue further development of SLN312 beyond Phase 1, with rights reverting to Silence
  • Generated promising preclinical data for SLN365 (GPR146) and SLN098 (INHBE) programs

Financial Impact

Revenue decreased by $42.7 million year-over-year, while net loss increased by $43.3 million

revenuenet losscash position

Risk Factors

  • High cash burn rate with increasing net losses
  • Dependence on successful clinical trial outcomes
  • Need to secure partnerships or additional funding for later-stage development

Market Snapshot

Exchange
OTC

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-092578
Document: sln-20260305.htm0001193125-26-092578
Document: sln-ex99_2.htm0001193125-26-092578
Document: 0001193125-26-092578-index-headers.html0001193125-26-092578
Document: 0001193125-26-092578-index.html0001193125-26-092578
Document: 0001193125-26-092578.txt0001193125-26-092578

Track record

15 reports on SLN

Performance horizon

4 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +28.19% at T+60 after the Aug 10, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $19.72 Now $19.80 +0.42% settles Nov 24
  2. Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $19.80 Now $19.80 −0.00% settles Nov 19
  3. Nov 12, 20264d ago DEFA14A Neutral 4/10 Entry $19.80 Now $19.80 −0.00% settles Nov 19
  4. Nov 12, 20264d ago 8-K Neutral 5/10 Entry $19.80 Now $19.80 −0.00% settles Nov 19
  5. Nov 5, 202611d ago SC 13G Neutral 4/10 Entry $19.72 to $19.80 Now $19.80 +0.41% ▲ +0.41% −2.88% vs SPY
  6. Oct 19, 202628d ago DEFA14A Bullish 7/10 Entry $19.61 to $19.78 Now $19.80 +0.97% ▲ +0.87% +0.79% vs SPY
  7. Oct 19, 202628d ago DEFA14A Bullish 8/10 Entry $19.58 to $19.78 Now $19.80 +1.12% ▲ +1.02% +1.17% vs SPY
  8. Oct 19, 202628d ago 8-K Bullish 9/10 Entry $19.58 to $19.78 Now $19.80 +1.12% ▲ +1.02% +1.17% vs SPY
  9. Oct 13, 20264w ago SC 13G/A Neutral 3/10 Entry $8.98 to $19.67 Now $19.80 +120.49% ▲ +119.04% +118.59% vs SPY
  10. Oct 13, 20264w ago SC 13G Neutral 3/10 Entry $8.98 to $19.67 Now $19.80 +120.49% ▲ +119.04% +118.59% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens in 6h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 5, 2026